Quick Takeaways: Why It Matters? Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio. Market-wise, a single injection providing up to three months of osteoarthritis pain...
Quick Takeaways Why It Matters? Gallant is on track to create one of the first mass‑market, disease‑modifying OA biologics in companion animals, shifting regenerative medicine from niche referral centers into everyday general practice via a simple, ready‑to‑use IV product. ...
Quick Takeaways: Why It Matters? ALA-1000’s data support a true once-monthly, long-acting analgesic option, which could meaningfully shift osteoarthritis pain management away from daily oral medications in suitable dogs. If approved, the combination of dura...
Quick Takeaways: Why It Matters? Data for LPT‑CBD strengthens the scientific case for long‑acting, injectable CBD as a legitimate chronic pain option, not just a wellness supplement, which can increase veterinarian openness to cannabinoid-based therapies. The sustaine...
